 |
|
|
| |
Risk-Based HCC Surveillance Strategies Using
HCC Risk Prediction Models
Have Greater Net Benefit Than the Current "One-Size-Fits-All" Strategy
In Patients who Received Antiviral Treatment for HCV
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
George N. Ioannou, Pamela Green, Lauren Beste, Elijah Mun,
Kathleen Kerr, Kristin Berry.
George N. Ioannou, BMBCh, MS, FAASLD
Director Hepatology
Veterans Affairs Puget Sound Health Care System
Professor of Medicine
University of Washington
SEATTLE
|
| |
|
|
|
|
|
